Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1

Leukemia. 2024 May 15. doi: 10.1038/s41375-024-02282-y. Online ahead of print.

Authors

Diletta Fontana¹, Federica Malighetti¹, Matteo Villa¹, Alfonso Zambon², Carlo Gambacorti-Passerini^{1

3}, Luca Mologni⁴

Affiliations

¹ Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
² Department of Chemistry and Geological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
³ Department of Hematology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
⁴ Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. luca.mologni@unimib.it.

PMID: 38750137
DOI: 10.1038/s41375-024-02282-y

No abstract available

Grants and funding